Hyperparathyroidism
📧 Sign up to get email alerts when something new happens for Hyperparathyroidism.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-02-08Clinical Trial Update: Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet [Phase 3]
Phase 3 head-to-head trial comparing etelcalcetide to cinacalcet in patients with secondary hyperparathyroidism and chronic kidney disease h…
-
FDA approval · 2017-02-07FDA Approved: PARSABIV — Original Application (Amgen, Inc)
FDA approved PARSABIV (etelcalcetide) in an Original Application (NDA 208325) by Amgen, Inc for the treatment of secondary hyperparathyroidi…
-
CLINICAL_TRIALS research · 2017-01-18Clinical Trial Update: Intravenous Paricalcitol in Chronic Hemodialysis Patients [Phase 4]
Phase 4 clinical trial update for intravenous paricalcitol in chronic hemodialysis patients; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2017-01-02Clinical Trial Update: Trial to Optimize Mineral Outcomes in Dialysis Patients [Phase 4]
Phase 4 clinical trial update evaluating mineral management in dialysis patients with secondary hyperparathyroidism; results have been poste…
-
CLINICAL_TRIALS trial_result · 2016-12-19Clinical Trial Update: Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease [Phase 1]
Phase 1 trial evaluating cinacalcet in children with chronic kidney disease completed with results posted in 2016.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-12-14FDA Approved: RAYALDEE — Supplemental Application (OPKO Pharmaceuticals LLC)
FDA approved a supplemental application for RAYALDEE (calcifediol) from OPKO Pharmaceuticals LLC.
-
FDA label_change · 2016-11-30FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for ZEMPLAR (paricalcitol) to update labeling and/or indications.
-
CLINICAL_TRIALS trial_result · 2016-11-21Clinical Trial Update: A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis [Phase 3]
Phase 3 pediatric safety trial evaluating paricalcitol capsules in children aged 10 to 16 with Stage 5 chronic kidney disease on dialysis; t…
-
CLINICAL_TRIALS trial_result · 2016-11-02Clinical Trial Update: Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery [Phase 1, Phase 2]
Clinical trial update on intra-operative infrared fluorescent imaging in thyroid and parathyroid surgery, with Phase 1 and Phase 2 completed…
-
FDA approval · 2016-10-18FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for ZEMPLAR (paricalcitol) submitted by AbbVie Inc.
-
FDA approval · 2016-10-07FDA Approved: PARICALCITOL — Original Application (MARKSANS PHARMA LIMITED)
The FDA has approved an original application for a generic paricalcitol from Marksans Pharma Limited. Paricalcitol is a vitamin D analog use…
-
CLINICAL_TRIALS trial_result · 2016-09-08Clinical Trial Update: Lipids Profile in Primary Hyperparathyroidism
The clinical trial investigating lipid profiles in primary hyperparathyroidism has been terminated.
-
CLINICAL_TRIALS research · 2016-09-05Clinical Trial Update: Pharmacoepidemiological Study of Secondary Hyperparathyroidism in Lorraine
A pharmacoepidemiological study conducted at Central Hospital in Nancy, France, examining secondary hyperparathyroidism in patients with end…
-
CLINICAL_TRIALS trial_result · 2016-08-25Clinical Trial Update: Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) [Phase 2, Phase 3]
CTAP101 was evaluated in patients with chronic kidney disease and secondary hyperparathyroidism in Phase 2/3 safety and efficacy trials; the…
-
CLINICAL_TRIALS trial_result · 2016-08-17Clinical Trial Update: Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency [Phase 3]
A Phase 3 trial evaluating CTAP101 for secondary hyperparathyroidism in CKD Stage 3-4 with vitamin D insufficiency has completed. Results ha…
-
CLINICAL_TRIALS trial_result · 2016-08-17Clinical Trial Update: Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency [Phase 3]
This Phase 3 clinical trial reports safety and efficacy results for CTAP101 in treating secondary hyperparathyroidism in patients with stage…
-
CLINICAL_TRIALS trial_result · 2016-08-17Clinical Trial Update: Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 [Phase 3]
OPKO Health's extension study of CTAP101-CL-3001 or CTAP101-CL-3002 has completed Phase 3 and posted results.
-
CLINICAL_TRIALS trial_result · 2016-08-09Clinical Trial Update: Study of the Influence of Dosages of 1-84 and 7-84 Fragments of Parathyroid Hormone Compared to Conventional Dosage on the Balance of Calcium and Phosphate in Hemodialysis (PTH) [NA]
This completed clinical trial evaluated the effects of two parathyroid hormone fragments, PTH (1-84) and PTH (7-84), compared with conventio…
-
CLINICAL_TRIALS research · 2016-07-26Clinical Trial Update: Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI) [NA]
The clinical trial update discusses localization of parathyroid adenoma using fluorocholine PET/MRI in primary hyperparathyroidism; the curr…
-
FDA approval · 2016-06-17FDA Approved: RAYALDEE — Original Application (OPKO Pharmaceuticals LLC)
The FDA approved RAYALDEE (calcifediol) from OPKO Pharmaceuticals as a new drug for adults with stage 3–4 chronic kidney disease and hypocal…
-
CLINICAL_TRIALS trial_result · 2016-05-25Clinical Trial Update: Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism [NA]
This completed clinical study examined whether serum periostin levels are associated with cortical porosity in patients with secondary hyper…
-
CLINICAL_TRIALS research · 2016-05-24Clinical Trial Update: The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis [NA]
This clinical trial investigates the efficacy and safety of microwave ablation for secondary hyperparathyroidism in patients undergoing main…
-
CLINICAL_TRIALS trial_result · 2016-05-23Clinical Trial Update: Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial
A completed prospective randomized trial comparing management strategies for asymptomatic primary hyperparathyroidism.
-
CLINICAL_TRIALS trial_result · 2016-05-02Clinical Trial Update: Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease [NA]
A completed clinical trial comparing cholecalciferol versus doxercalciferol for secondary hyperparathyroidism in chronic kidney disease; res…
-
CLINICAL_TRIALS trial_result · 2016-04-26Clinical Trial Update: The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients [Phase 2, Phase 3]
This trial update reports on a Phase 2/3 study evaluating the effects and safety of hemodialysis and hemoperfusion on renal osteodystrophy a…